Pulmonx Corporation Annual Revenue, Number of Employees, Growth and Funding
Estimated Revenue & Financials
- Pulmonx Corporation's estimated annual revenue is currently $36.1M per year.
- Pulmonx Corporation received $20.0M in venture funding in September 2014.
- Pulmonx Corporation's estimated revenue per employee is $234,701
- Pulmonx Corporation's total funding is $122M.
- Pulmonx Corporation has 154 Employees.
- Pulmonx Corporation grew their employee count by 26% last year.
- Pulmonx Corporation currently has 1 job openings.
|Narinder Singh Shargill||Vice President, Global Medical and Clinical Affairs|
|Beran Rose||Vice President, Marketing and Business Development|
|Lauren Cristina||VP, Finance and Administration|
|Gary Kennard||Director, Quality Assurance|
|Steve Wallace||Director of Operations|
|Sri Radhakrishnan||VP, R&D/ Director Clinical Affairs|
|Jim Bobbitt||Regional Business Director|
|Lisa Simmonds||Director, Supply Chain|
What Is Pulmonx Corporation?
Pulmonx is focused on developing life-changing technologies that improve the lives of patients suffering from lung disease. The Company's first commercial products address emphysema, a form of COPD (chronic obstructive pulmonary disease) and the largest unmet medical need in Pulmonology. With emphysema, breathing becomes increasingly more difficult as the disease progresses. Today in the U.S., advanced emphysema patients have no available alternatives but lung volume reduction surgery, which is associated with high morbidity and mortality, and lung transplantation, which is limited by the availability of donor organs. Pulmonx has developed the Zephyr Endobronchial Valve (EBV) Therapy, a non-surgical, investigational approach to treating emphysema. The minimally invasive Zephyr valve is a tiny, one-way valve designed to reduce the volume of the diseased regions of the lung by blocking airflow, in order to improve breathing and increase activity levels. No surgery is involved in the simple, one-hour procedure. More than 25,000 Zephyr valves have been implanted outside the U.S. in the last 10 years. Clinical studies in Europe have shown that the majority of qualified patients who have the procedure see a significant improvement in lung function, exercise tolerance and quality of life. In the United States, Pulmonx is conducting the LIBERATE Clinical Study to evaluate the safety and effectiveness of the Zephyr valve in patients with severe emphysema. Pulmonx products are commercially available in Europe, Australia, Asia, Latin America and other countries worldwide. The company does not yet market or sell its products in the United States. CAUTION: The Zephyr Endobronchial Valve is an investigational device in the US, limited by US law to investigational use.keywords:N/A
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Centro Medico D...||$19.8M||85||9%||N/A|
Pulmonx Corporation News
BUSINESS WIRE)--Pulmonx Corporation, a leader in therapeutic pulmonary device technologies, announced today that its Zephyr® Valve is ...
Pulmonx Corporation (Zephyr) and Spiration Inc are investing in the development and introduction of new endobronchial valve products. The Zephyr Valve ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx Corporation, a global leader in diagnostic and therapeutic pulmonary device ...
Pulmonx Corporation Funding
|2007-05-08||$20.4M||B-1||De Novo Ventures, Latterell Venture Partners||Article|
|2010-01-20||$11.5M||Undisclosed||De Novo Ventures, Latterell Venture Partners||Article|
|2014-09-18||$20.0M||Undisclosed||Oxford Finance LLC||Article|
Pulmonx Corporation Acquisitions
|2015-01-09||Aeris Therapeutics Inc||Article|